#Keymed
LightNews LightNews
endpts.com
There's a growing trend of Western investors boosting new companies to develop assets discovered in China. The latest? Tymberlyne Therapeutics nabbed $180M from Keymed Biosciences to develop a CD38-targeted monoclonal antibody.
endpts.com/another-biot...
Another biotech scoops up asset from China-based Keymed and nabs $180M
Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors propping up new companies to further develop assets discovered or initially cre...
endpts.com
January 10, 2025 at 2:55 PM
newsen.bsky.social
Keymed Biosciences Reports Impressive Annual Results for 2025 with Growth in Revenue and Product Launches#China#Beijing#Clinical_Trials#Keymed_Biosciences#Kangyueda
Keymed Biosciences Reports Impressive Annual Results for 2025 with Growth in Revenue and Product Launches
Keymed Biosciences achieved remarkable financial results in 2025, marking a significant increase in revenue alongside successful product launches and clinical advances.
third-news.com
March 27, 2026 at 3:50 PM
newsen.bsky.social
Keymed Biosciences Reports Impressive H1 2026 Financial Results and Business Milestones#China#Chengdu#Keymed_Biosciences#Kangyueda#CM336
Keymed Biosciences Reports Impressive H1 2026 Financial Results and Business Milestones
On August 19, 2026, Keymed Biosciences released notable financial results for the first half of 2026, showing significant growth and strategic advancements.
third-news.com
August 25, 2026 at 6:08 AM
newsen.bsky.social
Keymed Biosciences Announces Impressive H1 2026 Results and Strategic Developments#China#Chengdu#Keymed_Biosciences#Kangyueda#CM336
Keymed Biosciences Announces Impressive H1 2026 Results and Strategic Developments
Keymed Biosciences has reported significant growth in their interim results for H1 2026, showcasing remarkable revenue growth and strategic advancements in the pharmaceutical sector.
third-news.com
August 25, 2026 at 6:19 AM
newsen.bsky.social
Keymed Biosciences Releases Strong Financial Results and Updates for First Half of 2026#China#Chengdu#Keymed_Biosciences#Kangyueda#HKEX
Keymed Biosciences Releases Strong Financial Results and Updates for First Half of 2026
Keymed Biosciences has reported impressive revenue for the first half of 2026, showcasing significant growth driven by their flagship product, Kangyueda.
third-news.com
August 25, 2026 at 6:19 AM
l2plabs.bsky.social
Keymed Biosciences gibt Ergebnisse für das erste Halbjahr 2026 sowie aktuelle Geschäftsentwicklungen bekannt
CHENGDU, China, 25. August 2026 /PRNewswire/ -- Am 19. August 2026 gab Keymed Biosciences (HKEX: 02162) seine Zwischenergebnisse für das am 30. Juni 2026 endende Halbjahr mit einem Gesamtumsatz von 617 Millionen RMB bekannt. Das Kernprodukt Kangyueda erzielte einen Umsatz von 393...
dlvr.it
August 25, 2026 at 6:13 AM
l2plabs.bsky.social
Keymed Biosciences anuncia los resultados del primer semestre de 2026 y novedades empresariales
CHENGDU, China, 25 de agosto de 2026 /PRNewswire/ -- El 19 de agosto de 2026, Keymed Biosciences (HKEX: 02162) ha dado a conocer sus resultados provisionales para el semestre finalizado el 30 de junio de 2026, con unos ingresos totales de 617 millones de RMB. Su producto principal,...
dlvr.it
August 25, 2026 at 6:13 AM
l2plabs.bsky.social
Keymed Biosciences annonce ses résultats pour le premier semestre 2026 et fait le point sur ses activités
CHENGDU, Chine, 25 août 2026 /PRNewswire/ -- Le 19 août 2026, Keymed Biosciences (HKEX : 02162) a publié ses résultats semestriels pour la période close le 30 juin 2026, avec un chiffre d'affaires total de 617 millions de RMB. Le produit phare, Kangyueda, a généré un chiffre d'affaires de...
dlvr.it
August 25, 2026 at 6:09 AM
newsen.bsky.social
Keymed Biosciences Unveils Strong Interim Results and Future Prospects for 2026#China#Chengdu#Keymed_Biosciences#Kangyueda#CM336
Keymed Biosciences Unveils Strong Interim Results and Future Prospects for 2026
Keymed Biosciences reported impressive H1 2026 results with significant growth in revenue and profit, marking a positive trend for the biopharmaceutical sector.
third-news.com
August 21, 2026 at 9:24 AM
l2plabs.bsky.social
Keymed Biosciences Announces 2026 H1 Results and Business Updates
CHENGDU, China, Aug. 21, 2026 /PRNewswire/ -- On August 19, 2026, Keymed Biosciences (HKEX: 02162) announced its interim results for the six months ended June 30, 2026, with total revenue of RMB617 million. Core product Kangyueda generated sales of RMB393 million, up 132% YoY, supported...
dlvr.it
August 21, 2026 at 9:17 AM
newsen.bsky.social
Keymed Biosciences Reports Impressive 2026 H1 Financial and Development Achievements#China#Chengdu#pharmaceutical#Keymed_Biosciences#Kangyueda
Keymed Biosciences Reports Impressive 2026 H1 Financial and Development Achievements
In its latest report, Keymed Biosciences reveals significant growth in revenue and advancements in drug development for the first half of 2026, highlighting its strong dual-engine strategy.
third-news.com
August 20, 2026 at 2:48 PM
flipboardbr.flipboard.com.ap.brid.gy
Ações da Keymed Biosciences sobem com ganho de US$ 320 milhões do acordo Gilead-Ouro
https://br.investing.com/news/stock-market-news/acoes-da-keymed-biosciences-sobem-com-ganho-de-us-320-milhoes-do-acordo-gileadouro-1877886?utm_source=flipboard&utm_medium=activitypub

Posted into Economia & […]
Original post on flipboard.com
flipboard.com
March 24, 2026 at 8:59 AM
nbim-vote.bsky.social
Keymed Biosciences Inc. Annual meeting (2026-06-26) - NBIM voted against management:
• Against Management proposal: Elect Changyu Wang as…
See full meeting details.
June 25, 2026 at 9:40 AM
patesalo-e.bsky.social
Chengdu Kangnuoxing Biopharma and Keymed Biosciences patent new CDH17-targeting ADCs - BioWorld MedTech: Chengdu Kangnuoxing Biopharma and Keymed Biosciences patent new CDH17-targeting ADCs  BioWorld MedTech
Chengdu Kangnuoxing Biopharma and Keymed Biosciences patent new CDH17-targeting ADCs - BioWorld MedTech
Chengdu Kangnuoxing Biopharma and Keymed Biosciences patent new CDH17-targeting ADCs  BioWorld MedTech
news.google.com
December 13, 2025 at 12:00 AM
newsen.bsky.social
Keymed Biosciences Reports Their 2025 Annual Financial Results and Future Vision#China#Beijing#Keymed_Biosciences#Kangyueda#CMG901
Keymed Biosciences Reports Their 2025 Annual Financial Results and Future Vision
Keymed Biosciences has shared its annual financial results for 2025, highlighting a significant increase in revenue and breakthroughs in its product offerings.
third-news.com
March 26, 2026 at 7:19 PM
newsen.bsky.social
Keymed Biosciences Reports Significant Revenue Growth for 2025 and Updates on Business Developments#China#Beijing#Keymed_Biosciences#Kangyueda#CMG901
Keymed Biosciences Reports Significant Revenue Growth for 2025 and Updates on Business Developments
Keymed Biosciences has announced strong financial results for 2025, showcasing impressive revenue growth and strategic advancements in its product pipeline.
third-news.com
March 26, 2026 at 7:19 PM
newsen.bsky.social
Keymed Biosciences Reports Impressive Interim Results for 2025 with Accelerated Commercialization and R&D Momentum#China#Chengdu#Keymed_Biosciences#CMG901#Kang_Yue_Da
Keymed Biosciences Reports Impressive Interim Results for 2025 with Accelerated Commercialization and R&D Momentum
Keymed Biosciences Inc. has reported significant interim results for 2025, showcasing strong commercialization and innovative research developments that stand out in the biotech sector.
third-news.com
August 27, 2025 at 10:43 PM
newsen.bsky.social
Keymed Biosciences Announces Strong Interim Results for 2025 with Accelerated Commercialization and R&D Momentum#China#Chengdu#Stapokibart#Keymed#R&D_Progress
Keymed Biosciences Announces Strong Interim Results for 2025 with Accelerated Commercialization and R&D Momentum
Keymed Biosciences reports impressive interim results for 2025, showcasing accelerated commercialization and significant R&D advancements on various fronts.
third-news.com
August 27, 2025 at 7:05 PM
newsen.bsky.social
Keymed Biosciences Achieves Remarkable Interim Results for 2025#China#Chengdu#Keymed_Biosciences#Stapokibart#CMG901
Keymed Biosciences Achieves Remarkable Interim Results for 2025
Keymed Biosciences Inc. reports outstanding interim results for 2025, showcasing rapid commercialization and significant R&D advancements with strong financial performance.
third-news.com
August 27, 2025 at 2:14 PM
newsen.bsky.social
Keymed Biosciences Showcases Strong Interim 2025 Performance with Promising R&D and Commercialization Progress#China#Chengdu#AstraZeneca#Keymed_Biosciences#Stapokibart
Keymed Biosciences Showcases Strong Interim 2025 Performance with Promising R&D and Commercialization Progress
Keymed Biosciences achieved impressive interim 2025 results, highlighting robust revenue from its innovative drugs and a strategic focus on research and development.
third-news.com
August 27, 2025 at 6:26 AM
newsen.bsky.social
Keymed Biosciences Achieves Remarkable Interim Results in 2025, Highlighting Growth and Innovation#China#Chengdu#AstraZeneca#Keymed_Biosciences#Stapokibart
Keymed Biosciences Achieves Remarkable Interim Results in 2025, Highlighting Growth and Innovation
Keymed Biosciences has reported impressive interim results for 2025, showcasing significant revenue growth and advancements in R&D to enhance its market position.
third-news.com
August 27, 2025 at 6:04 AM
newsen.bsky.social
Keymed Biosciences Unveils Breakthrough Findings on CM336 in New England Journal of Medicine#None#Chengdu#Keymed_Biosciences#CM336#Autoimmune_Hemolytic_Anemia
Keymed Biosciences Unveils Breakthrough Findings on CM336 in New England Journal of Medicine
Keymed Biosciences has announced groundbreaking results from a clinical trial of CM336, targeting autoimmune hemolytic anemia, published in NEJM.
third-news.com
June 16, 2025 at 3:41 AM
newsen.bsky.social
Keymed Biosciences Unveils Promising Clinical Trial Results of CM336 for Autoimmune Hemolytic Anemia#China#Chengdu#Keymed_Biosciences#CM336#Autoimmune_Hemolytic_Anemia
Keymed Biosciences Unveils Promising Clinical Trial Results of CM336 for Autoimmune Hemolytic Anemia
Keymed Biosciences has announced groundbreaking outcomes from its clinical trial for CM336 treatment in autoimmune hemolytic anemia, highlighting significant patient remission.
third-news.com
June 15, 2025 at 2:01 AM
newsen.bsky.social
Keymed Biosciences Unveils Promising Clinical Trial Results for CM336 in Treating Refractory AIHA#China#Chengdu#Keymed_Biosciences#CM336#AIHA
Keymed Biosciences Unveils Promising Clinical Trial Results for CM336 in Treating Refractory AIHA
Keymed Biosciences announced significant findings from a clinical trial of CM336, showcasing its potential as an innovative treatment for autoimmune hemolytic anemia.
third-news.com
June 13, 2025 at 5:12 PM
newsen.bsky.social
Keymed Biosciences Breakthrough: CM336 A New Hope for Autoimmune Hemolytic Anemia#China#Chengdu#Keymed_Biosciences#CM336#autoimmune_treatment
Keymed Biosciences Breakthrough: CM336 A New Hope for Autoimmune Hemolytic Anemia
Keymed Biosciences presents positive results from a clinical trial for CM336, a bispecific antibody targeting autoimmune hemolytic anemia, published in NEJM.
third-news.com
June 13, 2025 at 10:03 AM